Edgewise Therapeutics

Forecast & Rating13 analysts currently cover Edgewise Therapeutics, with about 84.6% giving a positive rating — meaning they expect the stock to rise. The average price target is $52.62, about 33.0% upside from the current price of $39.57. Price targets range from $36.00 to $66.00 — a wide spread, showing clear disagreement over just how much Edgewise Therapeutics can rise. Historically, about 39.4% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Edgewise Therapeutics closely still see room for the stock to rise. Data as of Oct 5, 2026; for reference only and not investment advice.